Wave Life Sciences Ltd. (NASDAQ:WVE) is among the 12 Best Genomics Stocks to Invest In.
TheFly reports that on December 19, 2025, H.C. Wainwright upgraded Wave Life Sciences Ltd.’s price target from $22 to $30. Analyst Andrew Fein upheld the Buy rating. H.C. Wainwright cited 9.4% visceral fat loss and 3.2% lean mass gain with no gastrointestinal problems to support WVE-007 as a possible body recomposition agent, using key opinion leader validation and dose-response modeling. According to the firm, higher doses may expedite fat loss, and a clean safety profile supports a distinct commercial label.
Visible Alpha reported on the same day that Wave Life Sciences Ltd. shares soared by 147% on December 8 following the company’s presentation of preliminary clinical data for WVE-007, an RNA-based obesity therapy. Three months after a single dose, early data from a small research study revealed sustained fat reduction, including drops in visceral and total fat.
Visible Alpha consensus forecasts that risk-adjusted revenue for WVE-007 is expected to increase from $26 million to approximately $68 million in 2030 and from $1 billion to $2.1 billion by 2040. It is anticipated that by 2040, the drug candidate will account for 15% of the company’s revenue, climbing to 47%. The company’s total revenue is projected to reach $459 million in 2030 and $4.5 billion by 2040.
Wave Life Sciences Ltd. is a clinical-stage biotechnology firm dedicated to achieving the vast promise of RNA therapies, commonly known as oligonucleotides, which target RNA to transform human health.
READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.
Disclosure. None
